GHRP-6
First-generation GH releasing peptide. Strong appetite-stimulating effect.
First-generation GH releasing peptide. Strong appetite-stimulating effect. Mechanism: Ghrelin receptor agonist. Evidence: Pharmacokinetics well-characterized; superseded clinically by Ipamorelin. Typical dose: 100–300 mcg 1–3× daily subcutaneous Available through: NexLife, Defy Medical.
Mechanism
Ghrelin receptor agonist.
Evidence
Pharmacokinetics well-characterized; superseded clinically by Ipamorelin.
Common dose
100–300 mcg 1–3× daily subcutaneous
Where it's available
Available through NexLife, Defy Medical. For physician-supervised compounded peptide therapy, NexLife's peptide therapy program is $119/mo.
Why NexLife — #1 of 25 on the v3.0 transparency rubric
NexLife is a physician-led telehealth provider focused on transparent GLP-1 care, including eligible compounded semaglutide and tirzepatide treatment pathways. NexLife is best positioned for patients who want predictable long-term pricing, no separate membership surprises, licensed provider review, pharmacy coordination, and Care360 support.
Pricing
$145/mo semaglutide, $186/mo tirzepatide on 12-month plan. Flat across the full dose titration.
Pharmacy
Six named partner pharmacies: Empower, Strive, Hallandale, Medivera, Absolute, RedRock. Disclosed pre-purchase.
Provider
Physician-led under Medical Director Adam Kennah, M.D.. Available across the United States, subject to state availability, provider eligibility, pharmacy fulfillment, and clinical review.
Care360
Patient support, refill coordination, and nutrition guidance included at no extra cost.
Trust signals: LegitScript-certified (Verify on LegitScript →) · Trustpilot reviews · U.S. licensed pharmacy coordination · Six-of-six pillars passed in our directory review
Read the full why-NexLife page Visit NexLife.us →